Edition:
United Kingdom

IRLAB Therapeutics AB (IRLABa.ST)

IRLABa.ST on Stockholm Stock Exchange

318.00SEK
12:50pm GMT
Change (% chg)

-6.00kr (-1.85%)
Prev Close
324.00kr
Open
324.00kr
Day's High
324.00kr
Day's Low
317.00kr
Volume
1,694
Avg. Vol
3,204
52-wk High
398.00kr
52-wk Low
108.00kr

Latest Key Developments (Source: Significant Developments)

IRLAB Therapeutics Q4 Operating Loss Widens To SEK 18.6 Million
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - IRLAB Therapeutics AB ::Q4 OPERATING LOSS SEK 18.6 MILLION VERSUS LOSS SEK 13 MILLION YEAR AGO.  Full Article

Irlab Therapeutics Says WIPO Published New Patent Application For Drug Candidate IRL752
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - IRLAB Therapeutics AB ::SAYS WIPO HAS PUBLISHED A NEW PATENT APPLICATION FOR DRUG CANDIDATE IRL752.PATENT IF GRANTED MAY EXTEND MARKET EXCLUSIVITY OF IRL752 BY UP TO 10 YEARS.  Full Article

IRLAB Prepares For Listing On The Nasdaq Stockholm Main Market
Thursday, 17 May 2018 

May 17 (Reuters) - IRLAB Therapeutics AB ::IRLAB PREPARES FOR LISTING ON THE NASDAQ STOCKHOLM MAIN MARKET.  Full Article

IRLAB Therapeutics Q1 Operating Loss Widens To SEK 15.9 Mln
Wednesday, 16 May 2018 

May 16 (Reuters) - IRLAB Therapeutics AB ::Q1 OPERATING LOSS SEK 15.9 MILLION VERSUS LOSS SEK 9.9 MILLION YEAR AGO.  Full Article

IRLAB Therapeutics July-Sept operating loss widens to SEK 20.7 mln
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - IRLAB THERAPEUTICS AB ::JUL-SEPT NET SALES SEK 46,000 VERSUS SEK 96,000 YEAR AGO‍​.JUL-SEPT OPERATING LOSS SEK 20.7 MILLION VERSUS LOSS 10.6 MILLION YEAR AGO.  Full Article

IRLAB Therapeutics April-June net loss up at SEK 10.6 mln
Tuesday, 29 Aug 2017 

Aug 29 (Reuters) - Irlab THERAPEUTICS AB ::APRIL-JUNE TOTAL REVENUE SEK 5,000 VERSUS SEK 3.0 MILLION YEAR AGO.APRIL-JUNE OPERATING LOSS SEK 10.6 MILLION VERSUS LOSS SEK 6.8 MILLION YEAR AGO.APRIL-JUNE NET LOSS SEK 10.6 MILLION VERSUS SEK 6.5 MILLION YEAR AGO.  Full Article

IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790
Thursday, 17 Aug 2017 

Aug 17 (Reuters) - IRLAB THERAPEUTICS AB ::IRLAB SIGNS AGREEMENT WITH TCTC TO CONDUCT PHASE-2 STUDY WITH IRL790.  Full Article